(Q60448478)
Statements
AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate (English)
Barbara C Vanderhyden
12 December 2006
1 reference
scientific article published on 12 December 2006